"Icon Cancer Centre South Brisbane offers a full range of cancer treatments and blood disorder treatments. The centre is located in the Mater precinct with direct access to Mater Private Hospital. Treatment options include chemotherapy, immunotherapy, targeted therapies, apheresis and treatment for blood disorders. Icon has access to dedicated cancer care coordinators, scalp cooling systems, clinical trials, pharmacy and allied health services. There is no wait list, ensuring patients receive immediate access to consultation and treatment. The centre has a team of caring medical oncologists, haematologists, oncology nurses and administrative staff. Parking is available at Mater Private Medical Centre."

During the past decade, Icon Cancer Care South Brisbane conducted 41 clinical trials. In the 10-year time frame, 41 clinical trials started and 17 clinical trials were completed, i.e. on average, 41.5% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 13 clinical trials were completed. i.e. 86.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Icon Cancer Care South Brisbane" #1 sponsor was "Pfizer" with 11 trials, followed by "BeiGene" with 4 trials sponsored, "Atridia Pty Ltd." with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored and "Janssen Research & Development, LLC" with 3 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Icon Cancer Care South Brisbane" #1 collaborator was "Astellas Pharma Inc" with 6 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 5 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Medivation, Inc." with 2 trials as a collaborator and "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Icon Cancer Care South Brisbane" are "Prostate Cancer" (6 trials), "Breast Cancer" (3 trials), "Advanced Solid Tumor" (2 trials), "Advanced Solid Tumors" (2 trials) and "Cancer of the Prostate" (2 trials). Many other conditions were trialed in "Icon Cancer Care South Brisbane" in a lesser frequency.

Most popular intervention types in "Icon Cancer Care South Brisbane" are "Drug" (45 trials), "Biological" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Enzalutamide" (5 trials), "Abiraterone" (3 trials), "Docetaxel" (3 trials) and "Prednisone" (3 trials). Other intervention names were less common.

The vast majority of trials in "Icon Cancer Care South Brisbane" are 32 trials for "All" genders, 10 trials for "Male" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Icon Cancer Care South Brisbane". undefined are not yet recruiting, 12 are recruiting, 17 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Icon Cancer Care South Brisbane, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Icon Cancer Care South Brisbane, 13 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".